公开(公告)号：US20240150753A1

公开(公告)日：2024-05-09

申请号：US18475885

申请日：2023-09-27

Applicant: Illumina, Inc.

Inventor： Allison Yunghans ,  Angelica Marie Barr Schalembier ,  Kayla Busby ,  Stephen M. Gross ,  Robert Scott Kuersten ,  Frederick W. Hyde

IPC: C12N15/10 ,  C12N9/12 ,  C12N9/22

CPC classification number: C12N15/1096 ,  C12N9/1252 ,  C12N9/1276 ,  C12N9/22

Abstract: Described herein are compositions and methods for preparing double-stranded complementary DNA (cDNA) from RNA. In some embodiments, these methods allow isothermal preparation of cDNA. In some embodiments, these methods allow mesophilic or thermostable preparation of cDNA. Also described herein are compositions and methods for preparing cDNA and a library of double-stranded cDNA fragments in a single reaction vessel.

公开(公告)号：US20240182881A1

公开(公告)日：2024-06-06

申请号：US18538262

申请日：2023-12-13

Applicant: ILLUMINA, INC.

Inventor： Dewei Joel Toh ,  Leslie Yee Ming Beh ,  Shu Ting Tan ,  Anna Traczyk ,  Saurabh Nirantar ,  Eric Brustad ,  Hamed Tabatabaei Ghomi ,  Zahra Fahmi ,  Lekha Ravichandraprabhu ,  Colin Brown ,  Kayla Busby ,  Stephen Gross ,  Rebekah Karadeema ,  Huy Lam ,  Pascale Mathonet ,  Sarah E. Shultzaberger ,  Kathleen Tzeng ,  Allison Kathleen Yunghans

IPC: C12N9/78

CPC classification number: C12N9/78 ,  C12Y305/04005

Abstract: The present disclosure is concerned with proteins, methods, compositions, and kits for mapping of methylation status of nucleic acids, including 5-methylcytosine and 5-hydroxymethyl cytosine (5 hmC). In one embodiment, proteins are provided that selectively act on certain modified cytosines of target nucleic acids and converts them to thymidine or modified thymidine analogues. In another embodiment, proteins are provided that selectively act on certain modified cytosines of target nucleic acids and converts them to uracil or thymidine and selectively do not act on other certain modified cytosines of target nucleic acids. Also provided are compositions and kits that include one or more of the proteins and methods for using one or more of the proteins.

公开(公告)号：US20240175010A1

公开(公告)日：2024-05-30

申请号：US18476486

申请日：2023-09-28

Applicant: Illumina, Inc.

Inventor： Allison Yunghans ,  Angelica Marie Barr Schalembier ,  Kayla Busby ,  Stephen M. Gross

IPC: C12N15/10 ,  C12N9/00 ,  C12N9/22 ,  C12N9/24 ,  C12Q1/6874

CPC classification number: C12N15/1082 ,  C12N9/22 ,  C12N9/2497 ,  C12N9/93 ,  C12N15/1096 ,  C12Q1/6874 ,  C12Y302/0202 ,  C12Y302/02023 ,  C12Y302/02027 ,  C12Y302/02029 ,  C12Y605/01001

Abstract: Disclosed herein is a modified transposon end sequence comprising a mosaic end sequence, wherein the mosaic end sequence comprises one or more mutation as compared to a wild-type mosaic end sequence, wherein the mutation comprises a substitution with a uracil, an inosine, a ribose, an 8-oxoguanine, a thymine glycol, a modified purine, or a modified pyrimidine. Also disclosed are transposome complexes comprising these modified transposon end sequences and methods of library preparation using these modified transposon end sequences.